Alluvi, formerly BI 4744, represents a notable development in obesity care. This dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide sites demonstrates impressive effectiveness in https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/